Modified Immune Cells (TAG72-CAR T Cells) for the Treatment of Patients With Platinum Resistant Epithelial Ovarian Cancer
Part of paid clinical trials in Duarte, California.
- Sponsor
- City of Hope Medical Center
- Study ID
- NCT05225363
- Phase
- PHASE1
- Status
- Recruiting
Conditions
- Platinum-Resistant Ovarian Carcinoma
Eligibility Criteria
- Sex
- FEMALE
- Age
- 18 Years - N/A
- Healthy Volunteers
- Not accepted
Interventions
- Chimeric Antigen Receptor T-cells — BIOLOGICALReceive TAG72-CAR T cells IP
- Cyclophosphamide — DRUGGiven IV
- Fludarabine — DRUGGiven IV
Study Details
This phase I trial tests the safety, side effects, and best dose of TAG72-chimeric antigen receptor (CAR) T cells in treating patients with epithelial ovarian cancer that remains despite treatment with platinum therapy (platinum resistant). T cells are infection fighting blood cells that can kill tumor cells. The T cells given in this study will come from the patient and will have a new gene put in them that makes them able to recognize TAG72, a protein on the surface of tumor cells. These TAG72-specific T cells may help the body's immune system identify and kill TAG72+ cancer cells.
Key Dates
- Start date
- May 5, 2022
- Status verified
- Jun 2025
- Primary completion
- Oct 5, 2026
- Completion
- Jun 5, 2027
Study Design
- Enrollment
- 33 participants (estimated)
- Allocation
- NA
- Intervention model
- SINGLE_GROUP
- Primary purpose
- TREATMENT
Arms
- Experimental: Treatment (TAG72-CAR T cells)Patients receive fludarabine IV and cyclophosphamide IV on days -5 to -3. Patients receive TAG72-CAR T cells IP on day 0.
Primary Outcome Measure
Incidence of dose limiting toxicities (DLTs) [ Time Frame: Up to 28 days ]
Central Contacts
- Lorna Rodriguez626-359-8111
Locations (1)
| Facility | City | State | ZIP | Site coordinators |
|---|---|---|---|---|
| City of Hope Medical Center | Duarte | California | 91010 | Lorna Rodriguez (PRINCIPAL_INVESTIGATOR) |
Find similar trials in Duarte, CA
By research site
Related Studies
- ONC201 Plus Weekly Paclitaxel in Patients With Platinum Refractory or Resistant Ovarian CancerPHASE2 · Recruiting · Ira Winer · Detroit, Michigan
- PLX038 for Treatment of Metastatic Platinum-resistant Ovarian, Primary Peritoneal, and Fallopian Tube CancerPHASE2 · Recruiting · Mayo Clinic · Rochester, Minnesota
- Repurposing Atovaquone for the Treatment of Platinum-Resistant Ovarian CancerPHASE2 · Recruiting · Emory University · Atlanta, Georgia
- MUC1-Activated T Cells for the Treatment of Relapsed and Resistant Ovarian CancerPHASE1 · Recruiting · Mayo Clinic · Scottsdale, Arizona